MedTrace Logo

CBD-based Therapy to Attenuate Non-bacterial Prostatitis Symptoms

NCT06968910 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-05-13

No results posted yet for this study

Summary

Efficacy and safety of the medical device rectal CANNEFF® SUP suppositories containing two active ingredients cannabidiol (CBD) and hyaluronic acid (HA) in alleviating non-bacterial prostatitis symptoms and improving quality of life in men will be evaluated.

Conditions

  • Prostatitis

Interventions

DEVICE

CANNEFF® SUP rectal suppositories

CANNEFF® SUP suppositories with cannabidiol (CBD = 100 mg) and hyaluronic acid (HA = 6.6 mg) as active ingredients

Sponsors & Collaborators

  • CB21 Pharma Ltd.

    collaborator UNKNOWN

  • Palacky University

    lead OTHER

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-04-01
Completion
2025-01-01

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06968910 on ClinicalTrials.gov